Advertisement
U.S. markets open in 2 hours 49 minutes

Sanofi (SNY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
47.83-0.46 (-0.95%)
At close: 04:00PM EDT
47.50 -0.33 (-0.69%)
Pre-Market: 04:58AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close48.29
Open48.04
Bid48.18 x 2200
Ask48.31 x 900
Day's Range47.74 - 48.12
52 Week Range42.63 - 57.82
Volume887,370
Avg. Volume1,709,008
Market Cap119.793B
Beta (5Y Monthly)0.44
PE Ratio (TTM)20.44
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.90 (3.97%)
Ex-Dividend DateMay 30, 2023
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
14% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for SNY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Sanofi
    Weekly Stock ListWe see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.
    Rating
    Fair Value
    Economic Moat
    23 hours agoArgus Research
View more
  • Bloomberg

    PE Firms Eye €7.5 Billion Buyout Financing for Sanofi Unit

    (Bloomberg) -- Potential bidders for Sanofi’s consumer health division are mulling debt packages of about €7.5 billion ($8.16 billion), according to people familiar with the matter, which would make it one of the biggest leveraged buyout financings in recent years.Most Read from BloombergApple Without AI Looks More Like Coca-Cola Than High-Growth TechUS Probing Indian Billionaire Gautam Adani and His Group Over Potential BriberyWhat Does the UAE Get for Its $35 Billion Investment in Egypt?Want t

  • Insider Monkey

    12 Most Profitable Biotech Stocks To Invest In

    In this piece, we will take a look at the 12 most profitable biotech stocks to invest in. If you want to skip our overview of the global biotechnology industry and the latest trends, then you can take a look at the 5 Most Profitable Biotech Stocks To Invest In. Biotechnology is the riskiest and […]

  • Zacks

    ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study

    ASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with eczema, who have previously been treated with Dupixent but did not achieve an adequate response.